Amicus Therapeutics Inc
NASDAQ:FOLD

Watchlist Manager
Amicus Therapeutics Inc Logo
Amicus Therapeutics Inc
NASDAQ:FOLD
Watchlist
Price: 9.9 USD 0.51% Market Closed
Market Cap: 3.1B USD

Wall Street
Price Targets

FOLD Price Targets Summary
Amicus Therapeutics Inc

Wall Street analysts forecast FOLD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FOLD is 16.78 USD with a low forecast of 11.11 USD and a high forecast of 23.1 USD.

Lowest
Price Target
11.11 USD
12% Upside
Average
Price Target
16.78 USD
70% Upside
Highest
Price Target
23.1 USD
133% Upside
Amicus Therapeutics Inc Competitors:
Price Targets
4974
Takara Bio Inc
46% Upside
CRVO
Diffusion Pharmaceuticals Inc
179% Upside
006280
Green Cross Corp
28% Upside
GILD
Gilead Sciences Inc
9% Upside
ONCO
Oncopeptides AB
1% Downside
CUV
Clinuvel Pharmaceuticals Ltd
114% Upside
BIIB
Biogen Inc
5% Upside
OPK
OPKO Health Inc
169% Upside

Revenue
Forecast

Revenue Estimate
Amicus Therapeutics Inc

For the last 13 years the compound annual growth rate for Amicus Therapeutics Inc's revenue is 28%. The projected CAGR for the next 3 years is 19%.

28%
Past Growth
19%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Amicus Therapeutics Inc

The compound annual growth rate of Amicus Therapeutics Inc's operating income for the next 3 years is 92%.

N/A
Past Growth
92%
Estimated Growth
Estimates Accuracy
2%
Average Beat

Net Income
Forecast

Net Income Estimate
Amicus Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-40%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is FOLD's stock price target?
Price Target
16.78 USD

According to Wall Street analysts, the average 1-year price target for FOLD is 16.78 USD with a low forecast of 11.11 USD and a high forecast of 23.1 USD.

What is Amicus Therapeutics Inc's Revenue forecast?
Projected CAGR
19%

For the last 13 years the compound annual growth rate for Amicus Therapeutics Inc's revenue is 28%. The projected CAGR for the next 3 years is 19%.

What is Amicus Therapeutics Inc's Operating Income forecast?
Projected CAGR
92%

The compound annual growth rate of Amicus Therapeutics Inc's operating income for the next 3 years is 92%.

Back to Top